Brought to you by 
Series A leads to €14mm for Orphazyme APS
03 Oct 2011
Executive Summary
Orphazyme APS (developing treatments for rare genetic disorders) has raised €14mm ($19.8mm) in its Series A financing from new investor Aescap Venture and returning shareholders Novo AS and Sunstone Capital.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Series A leads to €14mm for Orphazyme APS
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice